Gene therapy for inherited disorders might cause an immune response to the therapeutic protein. A solution would be to introduce the gene in the fetal or neonatal period, which should lead to tolerization. Lentiviral vectors mediate long-term gene expression, and are well suited for gene therapy early in development. A model for fetal or neonatal gene therapy is the inherited disorder of bilirubin metabolism, Crigler-Najjar disease (CN). The absence of bilirubin UDP-glucoronyltransferase (UGT1A1) activity in CN patients causes high serum levels of unconjugated bilirubin and brain damage in infancy. CN is attractive for the development of gene therapy because the mutant Gunn rat closely mimics the human disease.
Introduction
A fundamental problem with gene therapy for inherited deficiencies is the potential of an immune response against the novel therapeutic gene product. Correction of deficiency could be short lived because the therapeutic transgene is seen as a foreign antigen by the immune system. This may cause the primed immune system to subsequently eliminate the corrected cells. An immune response to therapeutic transgenes has indeed been observed in a number of gene therapy studies.
1,2 A potential solution to this problem would be to exploit the tolerization that occurs to antigens that are introduced in the fetal and early neonatal period. Tolerization early in development has been well established, the first evidence of this phenomenon was provided by the landmark experiments performed by Billingham et al. 3 These studies showed that mice that were injected with heterologous cells shortly after birth, subsequently accepted skin grafts from the donor of the cells. Many experiments since have firmly established the induction of tolerance in the neonatal period. 4 These considerations have led to the development of gene therapy in fetal and neonatal animal models. [5] [6] [7] Several studies have established that fetal gene transfer can tolerize mice to foreign therapeutic proteins. Adenoviral and lentiviral clotting factor IX expression vectors were administered to fetal mice. When these mice were challenged with factor IX as adults, the immune response was absent or strongly reduced as compared to untreated mice. 8, 9 Our aim is to develop gene therapy for the severe inherited unconjugated hyperbilirubinemia in patients with Crigler-Najjar disease. Bilirubin is the breakdown product of the heme group of hemoglobin and other heme utilizing enzymes such as cytochrome P450s. As bilirubin is hydrophobic, it needs to be glucuronidated by the hepatic enzyme bilirubin UDP glucuronyltransferase (UGT1A1) before it can be excreted into bile. 10, 11 Patients with Crigler-Najjar type 1 (CN) have no detectable UGT1A1 activity and therefore have high serum levels of unconjugated bilirubin directly after birth. 12 Unconjugated bilirubin is highly neurotoxic, UGT1A1 deficiency leads to brain damage and death if not treated. 13 The only permanent treatment option for patients with CN is liver transplantation. The Gunn rat is a natural mutant that has no UGT1A1 activity and is therefore a good model for CN 14 and the development of fetal gene therapy for this disease. Tolerization to UGT1A1 is especially important because earlier studies have shown that UGT1A1 gene transfer in adult Gunn rats induces a strong humoral and cellular response to UGT1A1. 15 Gene therapy for inherited disorders requires longterm expression of the therapeutic transgene. Lentiviral vectors are retroviral vectors based on HIV and are well suited for the development of gene therapy for these disorders because they can efficiently transduce a wide variety of cell types in vivo and mediate long-term expression. [16] [17] [18] We have previously injected fetal Gunn rats with UGT1A1 lentiviral vectors and showed correction of hyperbilirubinemia. 19 When we injected similar doses of lentiviral vectors in neonatal Gunn rats, we observed a correction of hyperbilirubinemia that slowly decreased over time. This decrease in therapeutic effect was accompanied by the appearance of antibodies against human UGT1A1. When sera from in utero injected animals were tested retrospectively, we also found high titers of UGT1A1 antibodies.
Surprisingly, injection of GFP lentiviral vectors into fetal and neonatal animals did not lead to the formation of antibodies to GFP.
Our results therefore indicate that induction of tolerance is not necessarily the outcome of fetal or neonatal gene therapy. Furthermore, our results also suggest that UGT1A1 is a highly immunogenic protein which might explain the presence of UGT1A1 autoantibodies in autoimmune hepatitis.
Results

Correction of hyperbilirubinemia
We have previously demonstrated that administration of UGT1A1 lentiviral vectors to fetal Gunn rats corrected their deficiency. We now report that the difference in serum bilirubin between control and injected animals gradually disappears with loss of significance after 60 weeks ( Figure 1a) . Injection of UGT1A1 lentiviral vectors in neonatal Gunn rats (Figure 1b) led to a similar correction of hyperbilirubinemia that disappeared more rapidly with loss of significance at 18 weeks.
Demonstration of gene transfer
Bile analysis confirms that neonatal injection of UGT1A1 lentiviral vectors leads to functional expression of UGT1A1 ( Figure 2 ). However, as we have previously shown in fetally injected rats, the overall transduction efficiency was low. Qualitative PCR on chromosomal DNA confirmed the presence of viral integrations in liver, pancreas, spleen and intestine (not shown). All organs contained less than 1% of viral integrations, which precluded quantitative determination by real-time PCR.
Periferal blood mononuclear cells of animals injected with GFP lentiviral vectors contain a low percentage of GFP positive cells (not shown). Cryosections from animals injected neonatally with GFP lentiviral vectors shows that GFP expression in liver and pancreas persist for more than 5 months (Figure 3 ). Clusters of GFP positive cells were seen in pancreas and liver. Counting of at least three microscopic fields revealed that the total number of positive cells was below 1%, confirming our PCR data. Interestingly, only GFP positive hepatocytes were seen. This is in contrast to the preferential transduction of Kupffer cells by lentiviral vectors injected in the portal vein of adult mice. 20 
Antibodies to UGT1A1
High titers of antibodies to UGT1A1 were detected by ELISA in sera from rats injected in the fetal and neonatal period ( Figure 4 ). The antibodies were present at the first time point sampled, 4 weeks at the time of weaning. Titers increased and reached a plateau that was The specificity of the UGT1A1 antibodies was confirmed by Western blotting ( Figure 5 ). A band of 55 kDa was only seen when blots of cell lysates containing UGT1A1 were probed with serum from Gunn rats previously injected with UGT1A1 lentiviral vectors. The sera from UGT1A1 vector injected rats did not react with cell lysates containing GFP. Sera from Gunn rats injected with GFP lentiviral vectors did not contain antibodies reactive with GFP on Western blot, confirming the negative ELISA results.
Discussion
The strong immune response to lentivirally delivered UGT1A1 in fetal and neonatal rats contrasts with numerous observations, 7 including studies in Gunn rats, 21 that gene transfer in fetal and neonatal animals leads to tolerization to the transgene. An immune response to GFP has been observed in adult mice, 22 rats 23 and baboons, 24 which suggests that GFP is an immunogenic protein. We did not observe antibodies to GFP in animals injected in utero, or at the day of birth, with GFP vectors. Expression of GFP in liver and pancreas was sustained for more than 5 months in these animals, excluding a cellular immune response to GFP as well. This result was expected since a number of studies have shown that neonatal rats will only mount an immune response to exogenously administered antigens when they are at least 8 days old. 25, 26 A small number of studies have described immune responses in fetuses: fetal baboons could be immunized to hepatitis B virus by injection of an HBV vaccine, 27 an immune response to CMV was observed in prenatal children infected with this virus 28 and low titers of antibodies to beta galactosidase were observed after in utero injection of AAV or adenoviral beta galactosidase vectors in mice. 29 As fetal and neonatal rats do not mount an immune response to GFP but do respond to UGT1A1, a likely explanation of our results is that UGT1A1 is a highly immunogenic protein. Autoimmune hepatitis type 2 (AIH) is a disease of unknown origin which is characterized by the presence of liver kidney microsomal (LKM) antibodies. In 10% of AIH patients, these antibodies are directed against UDP glucuronosyltranferase 1 (UGT1). 30 Little is known about the role of these antibodies and whether they are the primary cause for AIH. The highly immunogenic nature of UGT1A1 could explain why UGT1 autoantibodies are present in patients with autoimmune hepatitis.
In this study the human UGT1A1 gene was used. As the Gunn rat does not express rat UGT1A1 protein, 31 the human and rat isoforms are both foreign to the rat immune system. However, it remains possible that the xenogenic human UGT1A1 protein elicits a stronger immune response than endogenous rat UGT1A1.
The mechanism behind the slow decline in therapeutic efficiency of lentiviral UGT1A1 gene transfer is unclear. We investigated whether the immune response to 32 This exposed UGT could be recognized by the circulating antibodies, which would lead to immune elimination of the opsonized cells. This study extends earlier reports that lentiviral gene transfer can be highly immunogenic, 33 possibly because antigen-presenting cells are readily transduced by these vectors. 34 A solution to this problem would be to use tissue-specific promoters and thus prevent expression in antigen-presenting cells. 35 Indeed, a recent paper documents that liverspecific lentiviral UGT1A1 gene transfer in neonatal Gunn rats does not elicit a cytotoxic immune response 36 and mediates long-term correction of UGT1A1 deficiency. However, the presence of UGT1A1 antibodies was not investigated in this study.
Because we do now show that lentiviral UGT1A1 gene transfer is very immunogenic, it is necessary to rigorously test the absence of an immune response to UGT1A1 in animal studies before lentiviral vectors can be used in gene therapy trials for Crigler-Najjar disease.
Materials and methods
Construction and production of lentiviral vectors
An improved third generation self-inactivating lentiviral vector system was the basis of our lentiviral vector constructs and was used as described. 19 To generate PGKUGT1A1, the human UGT1A1 cDNA was cloned as a SpeI fragment into the XbaI site of the lentiviral transfer vector PGKGFP replacing the GFP gene of this vector. In these vectors, the phosphoglycerate kinase (PGK) promoter is driving expression of the transgene. Lentiviral vectors were generated by cotransfection of 293T cells and concentrated as described. 
Animal experiments
All animal experiments were approved by the AMC animal ethical committee. Timed pregnancies in Gunn rats were initiated and the day after the copulation was considered embryonic day 1.
Injection of virus in fetal Gunn rats were performed by anesthesis of pregnant Gunn rats by intramuscular injection of KAR mix: 4 ml ketamine (100 mg/ml), 2 ml Rompun (xylazine 20 mg/ml), 1 ml atropine (1 mg/ml), dose: 0.1 ml/100 g bodyweight. The abdomen was opened by an incision of approximately 5 cm and the uterine horns were exposed. The virus was injected, in a volume of 75 ml, with a 27 gauge needle. Injections were aimed at the liver, visible as a large dark spot, and peritoneal cavity. The animals were closed by suturing the abdominal wall and skin and the pregnancy was carried to term in a normal manner. Injection of virus in neonatal Gunn rats was performed within half a day after birth of the pups, injections were aimed at the liver.
Blood was collected by tail vein puncture under gas anesthesia in pediatric heparin tubes. Peripheral blood mononuclear cells were isolated for flow cytometry by lysing the whole blood using FACS lysing solution (Becton Dickinson) and washing twice with PBS. For bile collection rats were anesthesized by intraperitoneal injection of KAR mix as described above and bile was collected by canulation of the bile duct as described. 38 ELISA for rat antibodies to UGT1A1 and GFP UGT1A1 and GFP were expressed in 293T cells by calcium phosphate coprecipitation. Expression of UGT1A1 was confirmed by Western blotting and expression of GFP was confirmed by fluorescence microscopy and Western blotting. ELISA plates (Nunc) were coated overnight with 5 mg cellular lysate per well in 50 mM carbonate buffer pH 9.6. The wells were blocked with 1% gelatin in phosphate-buffered saline, washed and incubated with serial dilutions of Gunn Figure 5 Western blotting shows specificity of UGT1A1 antibodies. Lysates containing UGT1A1 or GFP were probed with serum from rats injected with UGT1A1 or GFP lentiviral vectors. Middle lanes are the molecular mass markers. Sera from UGT1A1 vector injected rats react with UGT1A1 containing lysates only. An antibody to UGT1A1 was included as positive control. GFP antibodies were not detected in sera from rats injected with GFP lentiviral vectors.
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ELISA's were always performed in duplicate with the same samples applied on UGT1A1 and GFP coated plates. Titers of antibodies were set as the dilution were the absorption of the well was twice the absorption of control wells without rat serum. For the determination of UGT1A1 antibody titers, the titer of the same sample on the GFP coated plate was subtracted to correct for aspecific binding.
Western blotting
Western blots were incubated with rat serum that had been diluted 500 times. The UGT1A1 antibody WP1 served as a positive control. 37 Antibodies were detected with anti mouse peroxidase (Biorad) or anti-rat peroxidase (Nordic) and ECL chemiluminescence reagent (Amersham-Pharmacia). Images were recorded using a lumi imager (Roche).
Analysis of genomic DNA
DNA of organs was isolated and used for PCR as described. 19 To reduce the risk of contamination, a forward primer in the U3 region (ctggaagggctaattcactc) and a reverse primer in the packaging region (ggtttccctttcgctttcag) were selected for amplification. This primer pair only amplifies the integrated provirus and not the transfer vector.
Quantitative PCR was performed on a lightcycler using FastStart DNA master SYBR Green I hot start reaction mix (Roche Applied Science). Primers specific for human UGT1A1 that did not amplify rat UGT1A1 were used. Forward: TTCAGAGGACGTGCAGACAG, reverse: CAAGGTGGCACCTATGAAGC. For calibration, dilutions of human genomic DNA were made in rat genomic DNA. After amplification, samples were retrieved from the light-cycler capilaries and electrophoresed on an agarose gel. Quantification was performed using software provided by the manufacturer. The detection limit of this method was 1%: samples that had a single amplification product on gel and amplification slopes and melting curves identical to the standards always contained more than 1% of human UGT1A1.
